Investor's Business Daily on MSN

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.
NBC 10 Philadelphia

Pfizer, Moderna, Johnson & Johnson: Comparing the 3 COVID Vaccines Now Available

With three coronavirus vaccines already approved for emergency use authorization in the U.S., how do the different available shots compare? Pfizer and Moderna's COVID vaccines have been available in ...
BioSpace

Billions More in M&A, Another Bidding War and More FDA Drama

Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high ...

Pfizer: Is This Pharma Giant Finally A Bargain

Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.

How Recent Moves Are Rewriting the Story for Pfizer

Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has ...
StockStory.org on MSN

Why Pfizer (PFE) Shares Are Sliding Today

Pfizer is down 5.1% since the beginning of the year, but at $25.25 per share, it is still trading close to its 52-week high ...
Morningstar

Johnson and Johnson Earnings: A Solid Third Quarter, and Orthopaedics Separation Makes Sense

Johnson & Johnson JNJ reported third-quarter results slightly ahead of consensus, inching up full-year guidance for reported revenue growth by 30 basis points to 5.7% at the midpoint while ...